Introducing the MaxQ AI ACCIPIO® Family
MaxQ AI is at the cutting-edge of innovative Medical Diagnostic Artificial Intelligence. We aspire to make a meaningful impact on stroke and brain trauma treatment across the world driven by the question “what is the cost of a missed intracranial hemorrhage (ICH)?”. By developing advanced artificial intelligence software platforms applied to acute healthcare indications, we strive to help empower care providers with solutions to make faster, more accurate decisions.
Our first platform of medical devices, Accipio, which means “to learn” in Latin, uses artificial intelligence for assessment of non-contrast head CT for intracranial hemorrhage (ICH) diagnosis and treatment. We envision revolutionizing acute care and treatment with the help of world-class clinical partners and state-of-the-art technology. MaxQ AI is globally influencing the new era of AI-empowered care, one that provides access to expert-level diagnosis and makes an important difference in patients’ and physicians’ lives.
The Impact of Augmented Intelligence on Stroke Treatment: Interview with Dr. Navdeep Sangha of Kaiser Permanente
Interview with Dr. Navdeep Sangha, who is a Neurologist with Kaiser Permanente Los Angeles Medical Center. He is the Co-Assistant Chief of Neurology, and the Director of the Kaiser Permanente Southern California TeleStroke Program. During the interview, Dr. Sangha shares his insight into how emerging technology such as AI-powered diagnostic solutions are poised to augment acute care providers in the detection of intracranial hemorrhage (ICH). He also shares a number of cases studies, and highlights how MaxQ AI’s ACCIPIO® ICH and Stroke platform has shown the potential to enhance the identification and prioritization of patients suffering from stroke, head trauma and other life-threatening conditions.
The Cost of Doing Nothing
Questions to Ask
ACCIPIO® 'To Learn' Platform
ACCIPIO® Future
Diagnostic Rule Out
Provides diagnostic rule-out of suspected ICH (currently in development)
Accipio Ix™
Identification & Prioritization
click for demo
Provides Automatic, Rapid, Highly Accurate Identification and Prioritization
Accipio Ax™
Slice-level Annotation
click for demo
Provides Automatic, Rapid, Highly Accurate Slice-level Annotation & Prioritization
ACCIPIO®Future
Location & Volume Annotation
click for demo
Provides lesion-level annotation & quantification of lesion volume of suspected ICH (currently in development)
MAXQ AI FEATURED PRODUCT:
Accipio Ax™
Provides automatic slice-level annotation of suspected ICH
MaxQ AI’s new addition to the ACCIPIO® Platform, Accipio Ax™, introduces automatic, rapid, highly accurate slice-level annotation and prioritization of suspected ICH in CT imaging. With Accipio Ax physicians in the acute care setting will be able to quickly and easily interpret CT imaging and determine the presence of a suspected ICH. Along with Accipio Ix™ which identifies and prioritizes suspected ICH cases, radiology teams will be able to efficiently process cases and make decisions to provide critical treatment faster. Accipio Ax produces the annotated slices in near real-time, eliminating the need for more data and analysis.
Radiology / ER Departments
Emergency Rooms and radiology departments are under enormous pressure. With a high number of patients to be treated and a finite number of doctors, achieving timely assessment and precision can be challenging.
The Accipio platform triages ICH patients to prioritize their cases, giving physicians and patients time they need for proper care and treatment. A missed ICH can have serious medical, economic, and social repercussions.
Greatly increases ICH detection and reduce missed ICHs through near real-time triage, annotation, and diagnostic rule-out – because every minute matters for TBI, trauma, and stroke patients.
Community Hospitals
Combined with the reality that many community facilities have only ED support, no radiologist to read or sub-specialty neuroradiologist to escalate the case to for assistance, there is often limited review of head CT.
In this setting, the lack of confidence in identifying ICH can lead to unwarranted institutional transfer, withholding life-saving stroke care, and resulting in delayed action.
This can have significant consequences to the patient, physician, and facility.
Academic Hospitals
In larger facilities, resources and escalation are not the primary issues.
Efficiency and high-volume control are the areas of greatest need. Having multiple head CT cases stacked in the queue, with no timely prioritization, is common.
Ever-escalating cases to neuroradiologists diverts attention from the patients that need it most.
Mobile Stroke Units (MSU) can transmit early imaging data that helps guide patient routing and preparation of on-arrival resources.
Stroke Centers
Enhanced escalation and intervention confidence, including mobilization of neurosurgery, thrombolysis and thrombectomy resources for the right care readied faster.
The recipient of the Mobile Stroke Unit or life-flight unit should provide the needed information, before they arrive, to determine if they should be sent to this facility or not.
Payor / Providers
Every patient deflected from stroke to wellness is a net benefit to the bottom line.
On average, $150,000 per year in costs is required for stroke support/rehab of a patient.7
This is typically comprised of major metro centers with a “hub” academic center and large, networked community facilities.
Compounded with the reality that many community facilities have only ED support, no radiologist to read or sub-specialty neuroradiologist to escalate the case to for help, there is a large unmet need.
Testimonials
At MaxQ AI, we are dedicated to revolutionizing the acute care setting with innovative ai solutions. our ACCIPIO® platform is geared toward improving treatment for head trauma and stroke care patients, while also streamlining facility workflow and empowering healthcare professionals. read what customers are saying about us and see why we’re inspired every day to do what we do.
